Evidence map›Paper›PMID 39603795›Full record

ArticleACS chemical neuroscience2024

Imidazo[2,1-

Indrė Misiu Naitė, Kamilė Mikalauskaitė, Martyna Paulauskaitė, Ru Ta Sniečkutė, Vytautas Smirnovas, Algirdas Brukštus, Mantas Žiaunys, Ieva Žutautė

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Synthesis of 2-Aryl-3-(organoselanyl)-4The Journal of organic chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Indrė Misiu NaitėInstitute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Naugarduko st. 24, Vilnius LT-03225, Lithuania.ORCID 0009-0009-1846-1239
Kamilė MikalauskaitėInstitute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, Vilnius LT-10257, Lithuania.
Martyna PaulauskaitėInstitute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Naugarduko st. 24, Vilnius LT-03225, Lithuania.
Ru Ta SniečkutėInstitute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, Vilnius LT-10257, Lithuania.
Vytautas SmirnovasInstitute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, Vilnius LT-10257, Lithuania.ORCID 0000-0002-1829-5455
Algirdas BrukštusInstitute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Naugarduko st. 24, Vilnius LT-03225, Lithuania.
Mantas ŽiaunysInstitute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio al. 7, Vilnius LT-10257, Lithuania.ORCID 0000-0002-8368-6188
Ieva ŽutautėInstitute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Naugarduko st. 24, Vilnius LT-03225, Lithuania.ORCID 0000-0001-9654-3875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insoluble amyloid fibrils accumulate in the intercellular spaces of organs and tissues, leading to various amyloidosis-related disorders in the human body. Specifically, Parkinson's disease is associated with the aggregation of alpha-synuclein. However, current treatments for Parkinson's primarily focus on managing motor symptoms and slowing disease progression. Efforts to prevent and halt the progression of these diseases involve the search for small molecular compounds. In this work, we synthesized imidazo[2,1-

Indexed as

alpha-SynucleinAmyloidThiazinesHumansProtein AggregatesProtein Aggregation, Pathologicalalpha-SynucleinAmyloidProtein AggregatesThiazinesalkynesalpha-synucleinamyloid aggregationAu catalysiscyclizationimidazoles

Identifiers

PMID39603795
PMCPMC11660147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.